MA27665A1 - Triazoles substitues diaryle comme bloqueurs des canaux sodiques - Google Patents
Triazoles substitues diaryle comme bloqueurs des canaux sodiquesInfo
- Publication number
- MA27665A1 MA27665A1 MA28481A MA28481A MA27665A1 MA 27665 A1 MA27665 A1 MA 27665A1 MA 28481 A MA28481 A MA 28481A MA 28481 A MA28481 A MA 28481A MA 27665 A1 MA27665 A1 MA 27665A1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- pain
- relates
- alone
- pharmaceutically acceptable
- Prior art date
Links
- YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical group C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 title 1
- 239000003195 sodium channel blocking agent Substances 0.000 title 1
- 150000003852 triazoles Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 7
- 238000000034 method Methods 0.000 abstract 3
- 208000002193 Pain Diseases 0.000 abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 206010065390 Inflammatory pain Diseases 0.000 abstract 1
- 108010052164 Sodium Channels Proteins 0.000 abstract 1
- 102000018674 Sodium Channels Human genes 0.000 abstract 1
- 208000005298 acute pain Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 238000002690 local anesthesia Methods 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- -1 triazole compounds Chemical class 0.000 abstract 1
- 208000009935 visceral pain Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne des composés triazole substitués par du biaryle, représentés par la formule (I), (II) ou (III), ou des sels acceptables sur le plan pharmaceutique de ceux-ci. L'invention concerne également un procédé de préparation de tels composés et des sels de ceux-ci, ainsi que des compositions pharmaceutiques renfermant une quantité efficace des composés selon l'invention, soit seuls, soit avec un ou plusieurs autres composés actifs sur le plan thérapeutique, et un excipient acceptable sur le plan pharmaceutique. L'invention concerne, en outre, des méthodes de traitement d'états associés à l'activité des canaux sodiques ou engendrés par celle-ci, notamment, par exemple, des douleurs aigues, des douleurs chroniques, des douleurs viscérales, des douleurs inflammatoires, des douleurs neuropathiques, l'épilepsie, le syndrome du côlon irritable, la dépression, l'anxiété, la sclérose en plaques et un trouble polaire, consistant à administrer une quantité efficace des composés selon l'invention, soit seuls, soit conjointement avec un ou plusieurs autres composés actifs sur le plan thérapeutique. L'invention concerne enfin un procédé d'anesthésie locale consistant à administrer une quantité efficace d'un composé selon l'invention, soit seul, soit conjointement avec un ou plusieurs composés actifs sur le plan thérapeutique, et un excipient acceptable sur le plan pharmaceutique.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45595203P | 2003-03-18 | 2003-03-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA27665A1 true MA27665A1 (fr) | 2005-12-01 |
Family
ID=33030073
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA28481A MA27665A1 (fr) | 2003-03-18 | 2005-09-06 | Triazoles substitues diaryle comme bloqueurs des canaux sodiques |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US7326726B2 (fr) |
| EP (1) | EP1606269B1 (fr) |
| JP (1) | JP4482554B2 (fr) |
| KR (1) | KR100737721B1 (fr) |
| CN (2) | CN101289428A (fr) |
| AR (1) | AR044503A1 (fr) |
| AT (1) | ATE412639T1 (fr) |
| AU (1) | AU2004221885C1 (fr) |
| BR (1) | BRPI0408407A (fr) |
| CA (1) | CA2519252C (fr) |
| CL (1) | CL2004000551A1 (fr) |
| CY (1) | CY1108720T1 (fr) |
| DE (1) | DE602004017438D1 (fr) |
| DK (1) | DK1606269T3 (fr) |
| EC (1) | ECSP056018A (fr) |
| EG (1) | EG25994A (fr) |
| ES (1) | ES2314387T3 (fr) |
| HR (1) | HRP20050816A2 (fr) |
| IS (1) | IS8001A (fr) |
| JO (1) | JO2480B1 (fr) |
| MA (1) | MA27665A1 (fr) |
| MX (1) | MXPA05009847A (fr) |
| MY (1) | MY142651A (fr) |
| NO (1) | NO20054775L (fr) |
| NZ (1) | NZ542205A (fr) |
| PE (1) | PE20041066A1 (fr) |
| PL (1) | PL1606269T3 (fr) |
| PT (1) | PT1606269E (fr) |
| RU (1) | RU2356897C2 (fr) |
| SI (1) | SI1606269T1 (fr) |
| TW (1) | TWI337605B (fr) |
| UA (1) | UA81660C2 (fr) |
| WO (2) | WO2004083190A1 (fr) |
| ZA (1) | ZA200506906B (fr) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE405840T1 (de) | 2002-12-19 | 2008-09-15 | Scripps Research Inst | Zusammensetzungen und verfahren zur stabilisierung von transthyretin und zur hemmung von transthyretin-fehlfaltung |
| MY142651A (en) * | 2003-03-18 | 2010-12-15 | Merck Sharp & Dohme | Biaryl substituted triazoles as sodium channel blockers |
| AU2004289694B2 (en) * | 2003-11-10 | 2010-05-13 | Merck Sharp & Dohme Corp. | Substituted triazoles as sodium channel blockers |
| JP2007538103A (ja) | 2004-05-20 | 2007-12-27 | ザ スクリップス リサーチ インスティテュート | トランスサイレチン安定化 |
| TW200728258A (en) | 2005-10-10 | 2007-08-01 | Glaxo Group Ltd | Novel compounds |
| ATE472529T1 (de) | 2005-10-10 | 2010-07-15 | Glaxo Group Ltd | Prolinamidderivate als natriumkanalmodulatoren |
| TW200730494A (en) | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
| JP2010516731A (ja) * | 2007-01-24 | 2010-05-20 | グラクソ グループ リミテッド | ２−メトキシ−５−（５−トリフルオロメチル−テトラゾール−１−イル）−ベンジル］−（２ｓ−フェニル−ピペリジン−３ｓ−イル）−アミンを含む医薬組成物 |
| CN101679319B (zh) | 2007-02-08 | 2014-07-09 | 辛塔医药品有限公司 | 用于治疗增生性病症如癌症的三唑类化合物 |
| CA2963784A1 (fr) | 2007-06-08 | 2008-12-18 | Mannkind Corporation | Inhibiteurs d'ire-1.alpha |
| PT2464645T (pt) | 2009-07-27 | 2017-10-11 | Gilead Sciences Inc | Compostos heterocíclicos fusionados como moduladores do canal de iões |
| WO2012003392A1 (fr) | 2010-07-02 | 2012-01-05 | Gilead Sciences, Inc. | Composés hétérocycliques condensés en tant que modulateurs des canaux ioniques |
| AU2012253653A1 (en) | 2011-05-10 | 2013-05-02 | Gilead Sciences, Inc. | Fused heterocyclic compounds as sodium channel modulators |
| NO3175985T3 (fr) | 2011-07-01 | 2018-04-28 | ||
| TWI622583B (zh) | 2011-07-01 | 2018-05-01 | 基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| RU2586330C2 (ru) | 2011-09-16 | 2016-06-10 | Пфайзер Инк. | Твердые формы ингибитора диссоциации транстиретина |
| WO2013131018A1 (fr) * | 2012-03-02 | 2013-09-06 | Zalicus Pharmaceuticals Ltd. | Inhibiteurs biaryle du canal sodique |
| TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| US9751869B2 (en) | 2013-03-15 | 2017-09-05 | Bristol-Myers Squibb Company | LXR modulators |
| ES2912881T3 (es) | 2014-12-23 | 2022-05-30 | Convergence Pharmaceuticals | Procedimiento para preparar derivados de alfa-carboxamida pirrolidina |
| JP6616244B2 (ja) * | 2015-05-29 | 2019-12-04 | 北興化学工業株式会社 | 新規なヒドロキシフェニルボロン酸エステルとその製造方法、およびヒドロキシビフェニル化合物の製造法 |
| CN112153968A (zh) | 2017-10-05 | 2020-12-29 | 生物基因公司 | 制备α-羧酰胺吡咯烷衍生物的工艺 |
| KR102512548B1 (ko) | 2017-12-22 | 2023-03-22 | 삼성디스플레이 주식회사 | 유기 전계 발광 소자 및 유기 전계 발광 소자용 함질소 화합물 |
| US20210002232A1 (en) * | 2018-03-09 | 2021-01-07 | Pi Industries Ltd. | Heterocyclic compounds as fungicides |
| CN108794413A (zh) * | 2018-06-25 | 2018-11-13 | 青岛科技大学 | 一种1,2,4-三氮唑-3-甲酰胺的合成方法 |
| CN108863965A (zh) * | 2018-06-25 | 2018-11-23 | 青岛科技大学 | 一锅法制备1,2,4-三氮唑-3-甲酰胺的方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US875782A (en) * | 1907-04-29 | 1908-01-07 | Walter H Cook | Fast-nut. |
| TW226993B (fr) * | 1992-05-29 | 1994-07-21 | Kumiai Chemical Industry Co | |
| US5455252A (en) | 1993-03-31 | 1995-10-03 | Syntex (U.S.A.) Inc. | Optionally substituted 6,8-quinolines |
| JP3682075B2 (ja) * | 1993-04-16 | 2005-08-10 | クミアイ化学工業株式会社 | トリアゾール誘導体及び殺虫、殺ダニ剤 |
| TW533205B (en) * | 1996-06-25 | 2003-05-21 | Novartis Ag | Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition |
| IT1292091B1 (it) * | 1997-06-05 | 1999-01-25 | Geange Ltd | Derivati eterociclici aromatici azotati,procedimento per la loro preparazione e loro impiego come antigestativi,immunosoppressori e |
| GB9726987D0 (en) | 1997-12-22 | 1998-02-18 | Glaxo Group Ltd | Compounds |
| ES2345921T3 (es) | 1999-03-26 | 2010-10-06 | Euro-Celtique S.A. | Pirazoles, imidazoles, oxazoles, tiazoles y pirroles sustituidos con arilo y su uso. |
| AR029489A1 (es) | 2000-03-10 | 2003-07-02 | Euro Celtique Sa | Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento |
| CA2445568A1 (fr) * | 2001-04-27 | 2002-11-07 | Vertex Pharmaceuticals Incorporated | Derives triazole inhibiteurs des kinases et leurs utilisations |
| US6797722B2 (en) * | 2002-05-03 | 2004-09-28 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole for the treatment of autoimmune diseases |
| ATE543497T1 (de) * | 2002-07-09 | 2012-02-15 | Bristol Myers Squibb Co | Substituierte heterozyklische derivate als mittel gegen diabetes und adipositas und verfahren |
| KR100467668B1 (ko) * | 2002-08-07 | 2005-01-24 | 씨제이 주식회사 | 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물 |
| KR100470075B1 (ko) * | 2002-11-21 | 2005-02-05 | 씨제이 주식회사 | 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물 |
| JO2397B1 (en) * | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| MY142651A (en) * | 2003-03-18 | 2010-12-15 | Merck Sharp & Dohme | Biaryl substituted triazoles as sodium channel blockers |
| AU2004289694B2 (en) * | 2003-11-10 | 2010-05-13 | Merck Sharp & Dohme Corp. | Substituted triazoles as sodium channel blockers |
-
2004
- 2004-03-11 MY MYPI20040842A patent/MY142651A/en unknown
- 2004-03-11 AR ARP040100789A patent/AR044503A1/es unknown
- 2004-03-12 NZ NZ542205A patent/NZ542205A/en not_active IP Right Cessation
- 2004-03-12 AU AU2004221885A patent/AU2004221885C1/en not_active Ceased
- 2004-03-12 CN CNA2008101000997A patent/CN101289428A/zh active Pending
- 2004-03-12 HR HR20050816A patent/HRP20050816A2/hr not_active Application Discontinuation
- 2004-03-12 WO PCT/US2004/007830 patent/WO2004083190A1/fr not_active Ceased
- 2004-03-12 CA CA002519252A patent/CA2519252C/fr not_active Expired - Fee Related
- 2004-03-12 EP EP04720360A patent/EP1606269B1/fr not_active Expired - Lifetime
- 2004-03-12 AT AT04720360T patent/ATE412639T1/de active
- 2004-03-12 DE DE602004017438T patent/DE602004017438D1/de not_active Expired - Lifetime
- 2004-03-12 US US10/799,230 patent/US7326726B2/en not_active Expired - Lifetime
- 2004-03-12 PT PT04720360T patent/PT1606269E/pt unknown
- 2004-03-12 WO PCT/US2004/007597 patent/WO2004083189A1/fr not_active Ceased
- 2004-03-12 CN CNA200480013089XA patent/CN1788002A/zh active Pending
- 2004-03-12 JP JP2006507122A patent/JP4482554B2/ja not_active Expired - Fee Related
- 2004-03-12 SI SI200430959T patent/SI1606269T1/sl unknown
- 2004-03-12 ES ES04720360T patent/ES2314387T3/es not_active Expired - Lifetime
- 2004-03-12 DK DK04720360T patent/DK1606269T3/da active
- 2004-03-12 BR BRPI0408407-1A patent/BRPI0408407A/pt not_active IP Right Cessation
- 2004-03-12 PL PL04720360T patent/PL1606269T3/pl unknown
- 2004-03-12 UA UAA200509759A patent/UA81660C2/ru unknown
- 2004-03-12 KR KR1020057017327A patent/KR100737721B1/ko not_active Expired - Fee Related
- 2004-03-12 RU RU2005132168/04A patent/RU2356897C2/ru not_active IP Right Cessation
- 2004-03-12 MX MXPA05009847A patent/MXPA05009847A/es active IP Right Grant
- 2004-03-14 JO JO200430A patent/JO2480B1/en active
- 2004-03-16 PE PE2004000280A patent/PE20041066A1/es not_active Application Discontinuation
- 2004-03-17 TW TW093107083A patent/TWI337605B/zh not_active IP Right Cessation
- 2004-03-17 CL CL200400551A patent/CL2004000551A1/es unknown
-
2005
- 2005-08-29 IS IS8001A patent/IS8001A/is unknown
- 2005-08-29 ZA ZA200506906A patent/ZA200506906B/xx unknown
- 2005-09-06 MA MA28481A patent/MA27665A1/fr unknown
- 2005-09-14 EC EC2005006018A patent/ECSP056018A/es unknown
- 2005-09-18 EG EGNA2005000548 patent/EG25994A/xx active
- 2005-10-17 NO NO20054775A patent/NO20054775L/no not_active Application Discontinuation
-
2008
- 2008-01-30 US US12/011,967 patent/US7572822B2/en not_active Expired - Lifetime
-
2009
- 2009-01-15 CY CY20091100054T patent/CY1108720T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA59968B1 (fr) | Composés de cyclobutyle dihydroquinoléine sulfonamide | |
| RU2203274C2 (ru) | Спироциклические ингибиторы металлопротеаз | |
| TN2009000544A1 (fr) | Derives de benzimidazole | |
| TNSN08270A1 (fr) | Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale | |
| NO20054775L (no) | Biaryl-substituerte triazoler som natriumkanalblokkere | |
| MA27389A1 (fr) | Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs. | |
| TN2009000428A1 (fr) | Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale | |
| TN2009000138A1 (fr) | Biaryl-ether-urees | |
| ATE196762T1 (de) | Arylsulfonamido-substituierte hydroxamsäure derivate als matrix-metalloproteinase inhibitoren | |
| MA33720B1 (fr) | Inhibiteurs peptiques cycliques de la replication du virus de l'hépatite c | |
| MA31497B1 (fr) | Nouveaux inhibiteurs peptidiques de la replication du virus de l'hepatite c | |
| WO2001081312A3 (fr) | Methode de traitement se basant sur l'utilisation de derives de phenyle et de biaryle comme inhibiteurs de prostaglandine e | |
| TNSN07349A1 (fr) | Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur | |
| MA27957A1 (fr) | Agents derivatifs de quinolinone comme inhibiteurs de tyrosine kinase | |
| MA27095A1 (fr) | Formes de sels de e-2 -methoxy-n-(3-(4-(3-methyl-pyridine-3-yloxy)-phenylamino)-quinazoline-6-yl)-allyl)-acetamide, leur preparation et leur utilisation contre le cancer | |
| MA32108B1 (fr) | Derives d'indazole | |
| TNSN05037A1 (fr) | Derives heterobiaryliques servant d'inhibiteurs de metalloproteinases de matrice | |
| TNSN04212A1 (fr) | Sels de tolterodine | |
| MA29566B1 (fr) | Composes chimiques | |
| CA2433039A1 (fr) | Agent pour le traitement prophylactique et therapeutique de la douleur neuropathique | |
| BRPI0409151A (pt) | uso de derivados de 10-hidróxi-10,11-diidrocarbamazepina para o tratamento de transtornos afetivos | |
| FR2521134A1 (fr) | Urees et thio-urees substituees, leur procede de preparation et leur application therapeutique comme medicaments anti-atherosclereux | |
| MA68743B1 (fr) | Composés et compositions pour le traitement d'états associés à l'activité du récepteur de lpa | |
| FR2405067A1 (fr) | Compositions pharmaceutiques contenant des derives monofonctionnels du psoralene pour le traitement des affections cutanees | |
| MA61866B1 (fr) | Préparation de dérivés de benzimidazolone servant de nouveaux inhibiteurs de diacylglycéride o-acyltransférase 2 |